Liisa Bayko
Stock Analyst at Evercore ISI Group
(4.44)
# 350
Out of 4,711 analysts
80
Total ratings
52.31%
Success rate
21.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Liisa Bayko
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Maintains: Outperform | $7 → $5 | $1.31 | +281.68% | 5 | Dec 16, 2024 | |
| CARM Carisma Therapeutics | Downgrades: In-Line | $4 → $0.7 | $0.42 | +67.50% | 2 | Dec 11, 2024 | |
| SVRA Savara | Downgrades: In-Line | $7 → $5 | $3.23 | +54.80% | 3 | Nov 13, 2024 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $30 → $35 | $20.59 | +69.99% | 4 | Oct 30, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $405 → $360 | $308.44 | +16.72% | 9 | Aug 8, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $210 → $260 | $245.44 | +5.93% | 1 | Jun 25, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: In-Line | $27 → $2 | $2.53 | -20.95% | 2 | Jun 18, 2024 | |
| ANTX AN2 Therapeutics | Maintains: In-Line | $7 → $2 | $1.26 | +58.73% | 3 | May 16, 2024 | |
| ETNB 89bio | Maintains: Outperform | $37 → $33 | $7.94 | +315.62% | 4 | May 15, 2024 | |
| AKRO Akero Therapeutics | Maintains: Outperform | $50 → $38 | $29.34 | +29.52% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $438 | $397.27 | +10.25% | 17 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $14 | $17.18 | -18.51% | 4 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $80 | $44.22 | +80.91% | 8 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $10 | $7.57 | +32.10% | 4 | Apr 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $9.56 | +88.28% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $25 | $8.25 | +203.03% | 1 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $62 | $6.28 | +887.26% | 4 | Jul 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $66 → $60 | $40.72 | +47.35% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $8.20 | +326.83% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $24 | $42.60 | -43.66% | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $30 | $9.59 | +212.83% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $10 | $3.21 | +211.53% | 1 | Feb 5, 2020 |
Editas Medicine
Dec 16, 2024
Maintains: Outperform
Price Target: $7 → $5
Current: $1.31
Upside: +281.68%
Carisma Therapeutics
Dec 11, 2024
Downgrades: In-Line
Price Target: $4 → $0.7
Current: $0.42
Upside: +67.50%
Savara
Nov 13, 2024
Downgrades: In-Line
Price Target: $7 → $5
Current: $3.23
Upside: +54.80%
Kiniksa Pharmaceuticals International,
Oct 30, 2024
Maintains: Outperform
Price Target: $30 → $35
Current: $20.59
Upside: +69.99%
Madrigal Pharmaceuticals
Aug 8, 2024
Maintains: Outperform
Price Target: $405 → $360
Current: $308.44
Upside: +16.72%
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Outperform
Price Target: $210 → $260
Current: $245.44
Upside: +5.93%
Aerovate Therapeutics
Jun 18, 2024
Downgrades: In-Line
Price Target: $27 → $2
Current: $2.53
Upside: -20.95%
AN2 Therapeutics
May 16, 2024
Maintains: In-Line
Price Target: $7 → $2
Current: $1.26
Upside: +58.73%
89bio
May 15, 2024
Maintains: Outperform
Price Target: $37 → $33
Current: $7.94
Upside: +315.62%
Akero Therapeutics
May 15, 2024
Maintains: Outperform
Price Target: $50 → $38
Current: $29.34
Upside: +29.52%
Apr 11, 2024
Upgrades: Outperform
Price Target: $438
Current: $397.27
Upside: +10.25%
Sep 22, 2023
Maintains: Outperform
Price Target: $30 → $14
Current: $17.18
Upside: -18.51%
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $44.22
Upside: +80.91%
Apr 20, 2023
Maintains: Outperform
Price Target: $13 → $10
Current: $7.57
Upside: +32.10%
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $9.56
Upside: +88.28%
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $8.25
Upside: +203.03%
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $6.28
Upside: +887.26%
Jun 23, 2022
Downgrades: In-Line
Price Target: $66 → $60
Current: $40.72
Upside: +47.35%
Nov 23, 2021
Initiates: Outperform
Price Target: $35
Current: $8.20
Upside: +326.83%
Jun 8, 2021
Initiates: Outperform
Price Target: $24
Current: $42.60
Upside: -43.66%
Nov 24, 2020
Reinstates: Outperform
Price Target: $30
Current: $9.59
Upside: +212.83%
Feb 5, 2020
Upgrades: Market Outperform
Price Target: $10
Current: $3.21
Upside: +211.53%